

Michael Morrison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/895185/publications.pdf>

Version: 2024-02-01

40
papers

1,067
citations

567281

15
h-index

434195

31
g-index

43
all docs

43
docs citations

43
times ranked

1444
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynamic consent: a patient interface for twenty-first century research networks. <i>European Journal of Human Genetics</i> , 2015, 23, 141-146.	2.8	476
2	Including all voices in international data-sharing governance. <i>Human Genomics</i> , 2018, 12, 13.	2.9	50
3	StemBANCC: Governing Access to Material and Data in a Large Stem Cell Research Consortium. <i>Stem Cell Reviews and Reports</i> , 2015, 11, 681-687.	5.6	49
4	Promissory futures and possible pasts: The dynamics of contemporary expectations in regenerative medicine. <i>BioSocieties</i> , 2012, 7, 3-22.	1.3	43
5	Towards "Engagement 2.0": Insights from a study of dynamic consent with biobank participants. <i>Digital Health</i> , 2015, 1, 205520761560564.	1.8	37
6	Patenting human pluripotent cells: balancing commercial, academic and ethical interests. <i>Human Reproduction</i> , 2010, 25, 14-21.	0.9	35
7	The European General Data Protection Regulation: challenges and considerations for iPSC researchers and biobanks. <i>Regenerative Medicine</i> , 2017, 12, 693-703.	1.7	33
8	Tensions in ethics and policy created by National Precision Medicine Programs. <i>Human Genomics</i> , 2018, 12, 22.	2.9	32
9	Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies. <i>American Journal of Bioethics</i> , 2018, 18, 36-48.	0.9	31
10	The evolution of withdrawal: negotiating research relationships in biobanking. <i>Life Sciences, Society and Policy</i> , 2014, 10, 16.	3.2	28
11	CRISPR in context: towards a socially responsible debate on embryo editing. <i>Palgrave Communications</i> , 2019, 5, .	4.7	24
12	Growth hormone, enhancement and the pharmaceuticalisation of short stature. <i>Social Science and Medicine</i> , 2015, 131, 305-312.	3.8	20
13	Genome editing: the dynamics of continuity, convergence, and change in the engineering of life. <i>New Genetics and Society</i> , 2020, 39, 219-242.	1.2	19
14	Beyond the "embryo question": human embryonic stem cell ethics in the context of biomaterial donation in the UK. <i>Reproductive BioMedicine Online</i> , 2010, 21, 868-874.	2.4	18
15	Exploring the Role of Dedicated Online Biotechnology News Providers in the Innovation Economy. <i>Science Technology and Human Values</i> , 2012, 37, 262-285.	3.1	18
16	Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. <i>Genome Medicine</i> , 2017, 9, 85.	8.2	17
17	Infrastructural expectations: exploring the promise of international large-scale induced pluripotent stem cell banks. <i>New Genetics and Society</i> , 2017, 36, 66-83.	1.2	15
18	Introduction to the article collection "Translation in healthcare: ethical, legal, and social implications". <i>BMC Medical Ethics</i> , 2016, 17, 74.	2.4	14

#	ARTICLE	IF	CITATIONS
19	“A good collaboration is based on unique contributions from each side” assessing the dynamics of collaboration in stem cell science. <i>Life Sciences, Society and Policy</i> , 2017, 13, 7.	3.2	14
20	Governance of research consortia: challenges of implementing Responsible Research and Innovation within Europe. <i>Life Sciences, Society and Policy</i> , 2020, 16, 13.	3.2	13
21	Reflection on the enactment and impact of safety laws for regenerative medicine in Japan. <i>Stem Cell Reports</i> , 2021, 16, 1425-1434.	4.8	12
22	Overdiagnosis, medicalisation and social justice: commentary on Carter et al(2016) “A definition and ethical evaluation of overdiagnosis”. <i>Journal of Medical Ethics</i> , 2016, 42, 720-721.	1.8	11
23	Regulating human stem cell research and therapy in low- and middle-income countries: Malaysian perspectives. <i>New Genetics and Society</i> , 2018, 37, 2-20.	1.2	10
24	Gene therapy regulation: could in-body editing fall through the net?. <i>European Journal of Human Genetics</i> , 2020, 28, 979-981.	2.8	10
25	Comparative lessons in regenerative medicine readiness: learning from the UK and Japanese experience. <i>Regenerative Medicine</i> , 2021, 16, 269-282.	1.7	7
26	Spatiotemporal readiness is key to preparing regenerative medicine for the clinic. <i>Regenerative Medicine</i> , 2021, 16, 229-235.	1.7	5
27	Traceability in stem cell research: from participant sample to induced pluripotent stem cell and back. <i>Regenerative Medicine</i> , 2016, 11, 73-79.	1.7	4
28	Making Cells Worthwhile: Calculations of Value in a European Consortium for Induced Pluripotent Stem Cell Banking. <i>Science As Culture</i> , 2019, 28, 46-69.	3.2	4
29	Valuing height: diagnosis, valuation and the case of idiopathic short stature. <i>Sociology of Health and Illness</i> , 2019, 41, 502-516.	2.1	4
30	Biomodifying technologies and experimental space: organisational and regulatory implications for the translation and valuation of health research. - <i>ESRC. Impact</i> , 2019, 2019, 63-65.	0.1	3
31	Between Scylla and Charybdis: reconciling competing data management demands in the life sciences. <i>BMC Medical Ethics</i> , 2016, 17, 29.	2.4	2
32	Research using free text data in medical records could benefit from dynamic consent and other tools for responsible governance. <i>Journal of Medical Ethics</i> , 2020, 46, 380-381.	1.8	2
33	Implications of secondary findings for clinical contexts. , 2020, , 155-201.		2
34	Making bio-objects mobile: behind the scenes of a translational stem cell banking consortium. <i>BioSocieties</i> , 0, , 1.	1.3	2
35	Biocapital and Innovation Paths: The Exploitation of Regenerative Medicine. , 2013, , 58-87.		1
36	Creative regulatory practices to develop stem-cell technology: the way forward for Malaysia. <i>Regenerative Medicine</i> , 2022, 17, 91-105.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Biomodifying the "natural": from Adaptive Regulation to Adaptive Societal Governance. Journal of Law and the Biosciences, 2022, 9, .	1.6	1
38	Response to Open Peer Commentaries on "Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies" American Journal of Bioethics, 2019, 19, W10-W13.	0.9	0
39	Biocapital and Innovation Paths. , 0, , .		0
40	Making translational value: Identifying "good targets" for clinical research on gene editing and induced pluripotent stem cell technologies. SSM Qualitative Research in Health, 2022, 2, 100131.	1.5	0